Skip to main content

Table 6 Initial source for RECIST only disease progression

From: Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression

Lesion type for PD

Visceral involvement

No visceral involvement

 

Number of patients (n (%))

TTP (months)

Number of patients (n (%))

TTP (months)

Enlarging existing lesion(s)

11 (50.0)

1.8 (1.6–2.7)

8 (26.7)

3.0(1.6–4.5)

Presence of new lesions(s)

11 (50.0)

3.1 (2.8–4.3)

22 (73.3)

3.8(3.0–4.8)

-multiple sites*

1 (4.5)

4.3

7 (23.3)

3.2(3.0–4.4)

-lymph node

1 (4.5)

3.1

6 (20.0)

1.9(1.8–4.4)

-visceral

9 (40.9)

3.0 (2.8–3.1)

9 (30.0)

4.2(3.3–4.9)

  1. *Multiple sites: initial disease progression by RECIST which involves more than one type of anatomic site or simultaneous progression by RECIST and BSLA
  2. TTP Time to progression